The current CLSI and EUCAST clinical susceptible breakpoint for 600 mg q12h dosing of ceftaroline (active metabolite of ceftaroline fosamil) for Staphylococcus aureus is 1 mg/L. Efficacy data for S. aureus infections with ceftaroline MIC 2 mg/L are limited. This study was designed to generate in-depth pharmacokinetic/ pharmacodynamics (PK/PD) understanding of S. aureus isolates inhibited by 2 mg/L ceftaroline using an in vitro hollow-fibre infection model (HFIM).
Introduction
MRSA is currently recognized as a major problem in hospitals throughout the world, causing various infections: skin and soft tissue infections, bone-tissue infections, endocarditis, bacteraemia and pneumonia. [1] [2] [3] [4] Ceftaroline is the active metabolite of ceftaroline fosamil, a cephalosporin that exhibits bactericidal activity against Gram-positive pathogens, including MRSA and Streptococcus pneumoniae, as well as non-ESBL-producing Enterobacteriaceae. 5, 6 Ceftaroline fosamil is currently approved at a dose of 600 mg q12h for the treatment of complicated skin and soft tissue infections and community-acquired pneumonia caused by these pathogens. The current CLSI and EUCAST clinical susceptibility breakpoint for ceftaroline fosamil against Staphylococcus aureus is 1 mg/L (CLSI has an intermediate breakpoint of 2 mg/L). 7, 8 Analysis of susceptibility data against S. aureus isolates collected from 28 countries in a global surveillance programme conducted in 2012 indicates that ceftaroline has good in vitro activity against S. aureus in most countries participating in the surveillance programme (ceftaroline MIC 50 and MIC 90 values of 0.5 and 1 mg/L, respectively). 9 However, there are a few countries in Latin America (2 out of 4 countries), South-East Asia (2 out of 6 countries) and Europe (4 out of 16 countries) where the MIC 90 of ceftaroline for MRSA is 2 mg/L. 9 An understanding of the molecular characteristics of MRSA isolates (ceftaroline MIC values of 2 mg/L) collected from some of these countries and the impact of these molecular substitutions on the ceftaroline pharmacokinetic/pharmacodynamic (PK/PD) target and efficacy in S. aureus is needed to evaluate whether ceftaroline could be used to treat MRSA infections with MIC 2 mg/L.
Efficacy and PK/PD understanding of ceftaroline has been investigated previously by various research groups using in vitro and in vivo infection models. [10] [11] [12] While these studies evaluated MRSA isolates with a wide MIC range, the PK/PD understanding and efficacy for isolates with MIC 2 mg/L have not been evaluated comprehensively as a limited number of isolates with higher MICs were evaluated and the molecular characterization of isolates was not known. Additionally, Phase 3 clinical trials in complicated skin and skin-structure infections [CANVAS 1 (NCT00424190), CANVAS 2 (NCT00423657) and COVERS (NCT01499277)] had limited success in enrolling patients with MRSA infections with MIC values of 2 mg/L in order to develop a clinical PK/PD relationship understanding for such isolates. 13, 14 In the absence of clinical data, this study was designed to gain in-depth non-clinical understanding of ceftaroline against high-MIC MRSA isolates. Specifically, the study was designed to evaluate the PK/PD target and efficacy of ceftaroline against contemporary diverse clinical MRSA isolates with MIC 2 mg/L in an in vitro hollow-fibre infection model (HFIM) using q8h dosing and to evaluate the impact of various commonly found substitutions in the penicillin-binding domain (PBD) or non-PBD (nPBD) on the PK/PD target of these isolates. Additionally, the PD response of clinical and laboratory-generated mutants (ceftaroline MIC values ranging from 2 to 32 mg/L) was investigated against simulated ceftaroline PK from a 600 mg q8h human ceftaroline fosamil dose in the HFIM.
Methods

Antimicrobial agents
Ceftaroline was obtained from Cerexa, Inc. (Oakland, CA, USA). Fresh stock solutions of the drug were prepared on the day of the experiment in Mueller-Hinton broth II (MHB II) (BBL, Sparks, MD, USA) or sterile water.
Microorganisms
MRSA isolates investigated were obtained from the AstraZeneca Research Collection (ARC) and translational science collection (TRN) maintained by the AstraZeneca Infection Division at Waltham, MA, USA. The original source of these isolates was the ceftaroline global surveillance programme conducted in 2012, known as Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE), and laboratory-generated mutants. 9, 15 The isolates were selected to represent different ceftaroline susceptibility patterns, the geographical distribution and the predominant molecular substitutions observed among S. aureus collected during the global surveillance programme. 9 The epidemiology and molecular and structural characteristics of the majority of isolates investigated have been published previously. 9, 15 For evaluating the PK/PD target, a total of 12 MRSA with diverse molecular characteristics were studied in the HFIM for 24 h (Table 1) . For studies carried out with the clinical 600 mg q8h dose, 12 isolates (clinical isolates and laboratory-generated mutants) with higher MICs (2-32 mg/L) were evaluated ( Table 2 ). The susceptibility studies using the CLSI broth microdilution method 7 and whole genome sequencing were performed as detailed in the Supplementary data (Methods), available at JAC Online.
HFIM
Fluctuating serum drug concentrations (non-protein bound) were simulated in the HFIM over the period of study to investigate bacterial responses relative to clinically relevant drug exposures. The design of the HFIM has been described in detail previously. 16, 17 The system simulated a onecompartment PK model with first-order elimination. For all HFIM studies ceftaroline (the active metabolite of ceftaroline fosamil) was utilized. A half-life of 2.5 h, infusion durations of 2 h and a q8h regimen were simulated in all the studies. 14, 18 This dosing regimen was selected to align with the Phase 3 clinical trial COVERS (NCT01499277), where a 600 mg q8h regimen with 2 h infusion has been evaluated in patients with complicated skin and soft-tissue infection with systemic inflammatory response or underlying comorbidities.
14 Ceftaroline is .87% stable at room temperature for the dosing duration of 24 h. 19 For PK/PD target evaluation, dose-ranging studies were performed with four to eight doses (ranging from 0.5 to 4.3 mg, q8h) per isolate, targeting exposures between 0% and 100% fT .MIC for 24 h. For studies where a 600 mg q8h clinical dose of ceftaroline fosamil was simulated, a free ceftaroline geometric mean C max of 15.2 mg/L (using 20% protein binding), observed in patients with complicated skin and skin-structure infections, 14 was targeted using human-like PK for 72 h.
On the day of the experiment, 15 mL of bacteria (1%10 6 cfu/mL) in log phase were introduced to the extra-capillary space of the hollow-fibre cartridge (FiberCell Systems Inc., Frederick, MD, USA) followed by compound administration except for the control arm. Serial samples were collected from hollow-fibre cartridges at various timepoints to assess bacterial burden and simulated drug exposures. PK samples were stored at #70 C until assayed by LC-MS/MS as detailed in the Supplementary data (Methods). Bacterial samples were diluted (serial 10-fold dilutions), plated on blood agar plates and incubated for 24 h at 35 C before the cfu were enumerated visually. Bacterial samples were also plated for enumerating resistant isolates as detailed in the Supplementary data (Methods). The lower limit of detection was 400 cfu/mL. The PK/PD analysis was performed as detailed in the Supplementary data (Methods).
Results
Characterization of MRSA isolates
The susceptibility data and molecular characteristics for the isolates used in the study are shown in Tables 1 and 2 . These isolates were collected from varied sources, such as intraabdominal and respiratory infections (data not shown). For a few clinical and laboratory-generated isolates (ceftaroline MICs ranging from 4 to 64 mg/L), a better response was observed in the HFIM than that expected with the corresponding exposure based on published literature. 10, 12 For example, an unusual stasis to 2 log 10 -kill response was observed with 0% fT .MIC , which could not be explained byceftaroline activity ( Figure S1 ). A probable reason for this enhanced response may be the interday susceptibility variations. MIC determination is highly sensitive to variations in several factors, such as size of inoculum and the time and temperature of incubation. Based on the previous understanding of the PK/PD target for ceftaroline, 10, 12 the response of these isolates seemed to suggest a 2-fold decrease in susceptibility. While a 2-fold variation in MIC is not unusual and considered acceptable, a conservative approach was applied for the PK/PD analysis, and for all isolates showing an enhanced effect a 2-fold lower MIC (half the CLSI broth microdilution MIC) correction was adopted for the analysis and response interpretation. The MIC values determined using the CLSI standard broth microdilution method and those apparent in the HFIM (estimated based on the response; not measured directly in the HFIM) are indicated in Tables 1 and 2 . To minimize confusion, MIC values reported throughout this report are the apparent MIC values believed to be prevalent in the HFIM studies.
PK
Correlations between predicted and observed PK profiles in the HFIM were acceptable (R 2 . 0.90). Table 3 .
PK/PD target evaluation in HFIM
A dose-dependent kill was observed for all isolates following q8h ceftaroline administration targeting exposures between 0% and 100% fT .MIC (Figures 2 and S2 ). Lower doses with targeted exposures from 0% to 15% fT .MIC initially showed a static response followed by regrowth at 24 h, whereas higher doses with exposures of 20% fT .MIC showed stasis or a substantial (1 to 4 log 10 ) reduction in log 10 cfu/mL at the end of 24 h. For lower doses where regrowth was observed, no ceftaroline-resistant isolates were recovered at 24 h with the exposures targeted in these HFIM experiments, suggesting that regrowth was due to inadequate exposure.
For PK/PD analysis, first isolates were modelled individually to obtain PK/PD targets ( Table 1) . The mean stasis, 1 log 10 -kill and 2 log 10 -kill PK/PD targets from the 12 isolates evaluated in the HFIM were 29%, 32% and 35% fT .MIC , respectively (Table 1) . No correlation was observed between number of substitutions in nPBD and the PK/PD target. Subsequently, a combined analysis was performed including all isolates. The cfu/mL changes observed with respect to percentage fT .MIC exposures for all isolates with MICs of 2 and 4 mg/L are shown in Figure 3 . The stasis, The higher MIC was obtained in broth microdilution testing while the lower MIC was assumed based on the observed PK and PD response in the HFIM studies. Based on the previously established exposure-response relationship for ceftaroline, the lower MIC was used for PK/PD analysis. NA, not applicable. The higher MIC was obtained in broth microdilution testing while the lower MIC was assumed based on the observed PK and PD response in the HFIM studies. Based on the previously established exposure-response relationship for ceftaroline, the lower MIC was used for PK/PD analysis. Values shown are mean + SD.
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1 log 10 -kill and 2 log 10 -kill targets obtained by combined analysis of all isolates were 27%, 31% and 35% fT .MIC , respectively. While there were only two isolates with MIC 4 mg/L, the overall trend for PK/PD magnitude observed with MIC 2 and 4 mg/L indicated that the ceftaroline MIC did not influence the PK/PD target, i.e. that the PK/PD target was independent of MIC ( Figure S3 ). The PK/PD targets obtained from the mean of individual isolates and combined analysis were very similar, indicating good agreement was observed between isolates with diverse molecular characteristics and ceftaroline MIC values. Additional analysis was performed using the CLSI broth microdilution MICs for all the isolates shown in Table 1 ; the stasis, 1 log 10 -kill and 2 log 10 -kill targets obtained were 22%, 27% and 32% fT .MIC , respectively, showing that MIC variability did not impact the PK/PD target for ceftaroline.
Pharmacodynamic response with 600 mg q8h human-simulated ceftaroline fosamil dose against diverse S. aureus isolates
For isolates with MIC values of 2 (n " 2) and 4 mg/L (n " 7), a rapid kill of 4 log 10 cfu/mL was obtained within 8-12 h of dose administration and bacterial growth suppression was sustained until 72 h (Figure 4 ). This was in line with the high exposure of 90%-100% fT .MIC obtained against these isolates with the 600 mg q8h dose (Table 3 ). In addition, no emergence of resistance was observed for isolates with ceftaroline MICs 4 mg/L. These isolates carried single or multiple substitutions in the nPBD and/or PBD of PBP2a and these results indicate that the clinical dose of 600 mg q8h could be used to treat S. aureus infections (ceftaroline MIC of 4 mg/L) carrying these substitutions. For the laboratory-generated mutant (ARC3824-8A mutant) with MIC 8 mg/L and carrying two mutations in the PBD (Table 2) , an exposure of 50% fT .MIC was achieved with the ceftaroline 600 mg q8h dose. This exposure resulted in initial killing followed by regrowth after 48 h. The regrowth observed at later timepoints suggests that exposure of .50% fT .MIC could be required for complete suppression of resistance development for a longer duration in HFIM for isolates inhibited by 8 mg/L ceftaroline. For laboratorygenerated isolates with MIC 32 mg/L (ARC3824-4B1 and ARC3824-4B2 mutants) almost no exposure above MIC (0% fT .MIC ) was achieved with the 600 mg q8h dose and no kill was observed in the HFIM.
When HFIM samples from these studies were plated on ceftaroline-supplemented plates (4%MIC) colonies were obtained for mutants with MICs 8 and 32 mg/L. These isolates were further evaluated for changes in ceftaroline susceptibility and sequenced. Isolates obtained from strains ARC3824-4B1 and ARC3824-4B2 did not show reproducible changes in MIC compared with the parental strain, suggesting transient or unstable change in susceptibility. In contrast, however, isolates obtained from strain ARC3824-8A showed a reproducible 2-fold increase in the ceftaroline MIC. Several representative isolates were sequenced and all were found to carry a single-nucleotide (T) insertion in the pbp4 abcA intergenic region. These substitutions were similar to the changes that have been observed in spontaneous resistance studies with ceftaroline. 15 
Discussion
The PK/PD characteristics of b-lactams have been studied extensively for decades. 20, 21 Ceftaroline PK/PD target evaluation has been published for S. aureus (MRSA and MSSA) isolates inhibited by 0.125-2 mg/L ceftaroline using an in vivo murine thigh infection model and an in vitro pharmacokinetic model. 10, 12 Andes and Craig evaluated a limited number of S. aureus isolates (two MSSA and two MRSA) with MICs ranging from 0.12 to 1mg/L in a neutropenic murine thigh infection model. 10 Using dose-ranging and dose-fractionation studies, the authors established the ceftaroline Ceftaroline PK/PD target evaluation for MRSA JAC percentage fT .MIC PK/PD index and stasis, 1 log 10 -kill and 2 log 10 -kill targets as 26%, 33% and 45% fT .MIC , respectively. 10 MacGowan et al. 12 utilized an in vitro single-compartment dilutional PK model to investigate a total of 12 S. aureus isolates (3 MSSA and 9 MRSA) with MIC values ranging from 0.12 to 2 mg/L. While more isolates were evaluated by MacGowan et al. as compared with Andes and Craig, only one isolate with MIC 2 mg/L was included. The stasis and 1 log 10 -kill targets derived from this work were similar to those reported by Andes and Craig, with mean values of 24.5% and 27.8% fT .MIC , respectively. However, the 2 log 10 -kill values reported in the dilutional PK model were lower, 27.7% fT .MIC , compared with those derived from the in vivo study. This difference could be partly due to difficulty in obtaining 2 log 10 kill with some isolates and higher variability observed for the maximum kill obtained with S. aureus isolates in the in vivo infection model.
The efficacy of human simulated exposures of ceftaroline 600 mg q12h was evaluated using murine thigh infection models by Keel et al. 11 A total of 26 S. aureus isolates (4 MSSA and 22 MRSA) with MIC values ranging from 0.12 to 4 mg/L were evaluated using neutropenic and immunocompetent murine models. 11 With exposures targeted between 27.5% and 100% fT .MIC for the isolates, a reduction of 0.95-3.28 log 10 cfu/mL in the neutropenic model and 1.06-2.43 log 10 cfu/mL in the immunocompetent model was achieved. The Keel et al.
11 study was the first to evaluate contemporary clinical isolates (n " 4) obtained from a surveillance programme inhibited by 4 mg/L ceftaroline and demonstrated the efficacy of ceftaroline 600 mg q12h against S. aureus with MICs of 4 mg/L. Although the Keel et al.
11 study was not designed to investigate the PK/PD target, a retrospective analysis of data pooled across isolates with different ceftaroline MIC values revealed stasis, 1 log 10 -kill and 2 log 10 -kill targets of 9.3%, 19.3% and 70.5% fT .MIC . The stasis targets of 9.3% fT .MIC were much lower compared with other studies because of a lack of data points in the steep portion of the exposure-response slope. Similar to Andes and Craig, 10 differential maximum killing was obtained, with only a few isolates achieving a 2 log 10 kill and hence the estimates derived for 2 log 10 -kill PK/PD target were higher.
In the current study a different in vitro system and q8h dosing was employed to evaluate the PK/PD target for ceftaroline. Results of the current study show good agreement with the published ceftaroline PK/PD target derived from in vitro and in vivo infection models. 10, 12 It is noteworthy that the 1 log 10 -kill target reported using three different models-MacGowan et al., 12 Andes and Craig 10 and our HFIM-were all in the range of 28%-33% fT .MIC , showing close in vitro-in vivo correlation for the ceftaroline PK/PD targets. This correlation was noted despite the PK difference between the in vivo mouse model used by Andes and Craig 10 (halflife 0.5-0.8 h) and our HFIM study (half-life 2.5 h) and has helped to consolidate the PK/PD target, thereby increasing the non-clinical understanding of ceftaroline efficacy in S. aureus infection.
While the above-mentioned studies [10] [11] [12] helped to develop ceftaroline PK/PD understanding, none of these studies reported the molecular characteristics of the isolates evaluated and hence the link between molecular characteristics and PK/PD targets was not known. The current study is the first to link PK/PD understanding to the molecular characteristics of isolates predominant across Singh et al.
different geographical locations and clinical settings (abscesses, wounds, respiratory infections etc.). These isolates represent major genotypic lineages prevalent in countries where higher ceftaroline MIC values have been observed. 9, 15 These PBP2a variations could be divided into two major categories. 9 In the first category isolates contained an E447K substitution in the transpeptidase-binding pocket of PBD and had ceftaroline MICs of 4 mg/L. The second category had variations in nPBD, with the majority of the isolates possessing E150K, E239K and/or N146K substitutions, and had ceftaroline MICs of 2 mg/L. Our data suggest that the PK/PD magnitude for MRSA is not impacted by the presence of nPBD substitutions commonly found in isolates inhibited by 2 mg/L ceftaroline. We further show that isolates inhibited by 4 mg/L ceftaroline, shown to carry one substitution in the PBD, demonstrated a PK/PD target similar to that of isolates inhibited by 2 mg/L. Thus, our data confirm that ceftaroline efficacy in HFIM is not significantly impacted by PBP2a sequence diversity, particularly changes present in the nPBD domain.
Our studies with the 600 mg q8h clinical dose of ceftaroline fosamil suggest that this dose could potentially be effective against S. aureus infections with ceftaroline MIC values of 4 mg/L. Similar results were reported previously by Vidaillac et al., 22 where no emergence of resistance was observed with ceftaroline 600 mg q12 h and 600 mg q8h dosing for isolates inhibited by 2 mg/L ceftaroline. In the current study we have further extended the observations of Vidaillac et al. 22 to include isolates inhibited by 4 mg/L ceftaroline for 600 mg q8h dosing. MacGowan et al.
12 evaluated multiple S. aureus isolates (ceftaroline MIC values of 2 mg/L) and reported no emergence of resistance using the ceftaroline 600 mg q12h dose. 12 Combined with results previously reported by MacGowan et al. 12 and Vidaillac et al., 22 these findings show that a 600 mg ceftaroline dose could potentially suppress emergence of resistance for isolates inhibited by 2 mg/L with q12h dosing and 4 mg/L with q8h dosing.
MacGowan et al. 12 reported that the PD response with the ceftaroline 600 mg q12h dose was independent of ceftaroline MIC. 12 These authors observed regrowth of the bacterial population for a few isolates but no emergence of resistance for isolates inhibited by 2 mg/L ceftaroline. This regrowth was surprising since the 600 mg q12h dose achieved adequate exposures (.82% fT .MIC ) against these isolates. Vidaillac et al. 22 also observed bacterial regrowth after 32 h for two isolates treated with ceftaroline 600 mg q8h and q12h. 22 This regrowth was not correlated to resistance, instability of the drug or tolerance. However, the study was conducted at a high inoculum (10 7 cfu/mL) and subpopulations with higher MIC values of ceftaroline were found by population analysis for these two isolates, which could explain the observed regrowth. In contrast to these two studies, we observed a predictable MIC-dependent response in our studies using 600 mg q8h and complete suppression of regrowth for clinical isolates inhibited by 4 mg/L ceftaroline. Regrowth and emergence of resistance were only observed at MIC 8 mg/L, where the exposures were 50% fT .MIC and the duration was .48 h. These findings are consistent with values reported by MacGowan et al.
12
While the starting inoculum of our study was lower (10 6 cfu/mL) than that used by Vidaillac et al., 22 we used the same inoculum as that of MacGowan et al. 12 and as such this is unlikely to explain the reason for the differences observed.
Finally, it should be noted that in vitro models such as HFIM have several limitations: they cannot mimic the host defence mechanisms, the pathology of the infection, the virulence behaviour of a pathogen and the variability of PK in patients, hence the results of our study may not be fully applicable in all clinical scenarios. 23 Additionally, while our studies with the 600 mg q8h clinical dose of ceftaroline fosamil show full growth suppression of S. aureus isolates with ceftaroline MIC values of 4 mg/L, the lower limit of detection was 400 cfu/mL and hence the emergence of resistance beyond 72 h due to any persisting bacteria cannot be ruled out. In the current study more than the expected killing was observed for a few isolates, which was considered an artefact of the susceptibility testing. While the PK/PD targets in our study were not affected by these changes in the susceptibility of the isolates, this does reflect the challenges posed by an MIC-based analysis. Errors in MIC have been shown to affect percentage fT .MIC more compared with other indices. 24 Using mechanistic PK/PD modelling can minimize the impact of these MIC errors. In our studies -P20 mutant  ARC3824-8A mutant  ARC3824-4B2 mutant  ARC3829  ARC6212  ARC3824  ARC5472  TRN6120  TRN5517 TRN6128 TRN6123 Figure 4 . PD response for ceftaroline against diverse S. aureus isolates evaluated in the HFIM for 72 h using 600 mg q8h dose.
Ceftaroline PK/PD target evaluation for MRSA JAC unbound mean plasma concentrations were assumed to drive efficacy. While ceftaroline has been shown to have good penetration in soft tissue and muscles (75% and 66%, respectively) in healthy volunteers, the haemodynamic changes in critically ill patients affecting the target site penetration may present challenges in the treatment of these patients. 25 Hence, the extrapolation of the conclusions from the present study to clinical practice should be done with caution.
In conclusion, these HFIM studies provide evidence of efficacy against diverse characterized MRSA isolates with ceftaroline MIC of 2 and 4 mg/L, and have helped to consolidate the PK/PD target and support the use of the 600 mg q8h ceftaroline fosamil dose to treat S. aureus, including MRSA, with MICs 4 mg/L.
